This project is focused on advancing **sustainable medicines manufacturing** by developing a cutting-edge **stable cell line** system to improve the production of adeno-associated virus (AAV), a key component in gene therapies. Current AAV production methods are costly and inefficient, particularly when scaling up to meet commercial demand. Our solution aims to create a reliable and **scalable** platform that will significantly increase production yields while reducing costs, making gene therapies more accessible and affordable for patients. A central goal of this project is to enhance **productivity** by streamlining the AAV production process. Current methods often suffer from variability in output and require significant resources. Our stable cell line system will address these inefficiencies, enabling **high-volume, consistent production** while reducing the time, labor, and materials required. This will lower the cost per dose, which is essential for the broader adoption of gene therapies. By improving **resource efficiency**, the technology ensures that manufacturers can produce more output with fewer inputs, making the production process both more productive and cost-effective. Furthermore, the system will contribute to more **sustainable manufacturing** practices by optimizing resource use and minimizing waste. The stable cell line platform will allow manufacturers to meet **regulatory standards** with greater ease, ensuring consistent production quality even at a larger commercial scale. This consistency is vital for the safe and effective production of gene therapies, ensuring that patients receive high-quality treatments. In addition to its impact on productivity and sustainability, the project will foster broader collaboration within the **gene therapy industry**. By creating a platform that can be easily adopted across the sector, we aim to support partnerships between manufacturers, researchers, and healthcare providers. These collaborations will enhance manufacturing capabilities and increase access to innovative treatments. Overall, this project has the potential to transform AAV manufacturing by significantly improving **productivity**, **scalability**, and **sustainability**, helping to make gene therapies more affordable and widely available.

Cell therapies are the next generation of medicines that can potentially cure many diseases including diabetes, heart disease or cancer. While there are some promising approaches already, bringing these treatments to broad application requires improvements in the scale and cost. Pluripotent stem cell derived therapies have the power to do this and can be the key to treat some illnesses that are without a cure so far. However, making the right cell types (e.g. pancreatic cells, heart cells or immune cells) from stem cells can be difficult and lead to some unwanted cells that are either not beneficial for the patient or, in the worst case, can be dangerous. Therefore we need to make sure that cells for therapeutic purposes are clean and safe to use. Plurify is developing a new approach to ensure exactly that. With our technology, we can purify any specific cell type from a mixture of cells that is usually produced when trying to make cells for therapy. This new method can solve one of the key bottlenecks that have been holding back pluripotent stem cells from fulfilling their true potential for cell therapies. With the help of Innovate UK funding, we will be able to develop this technology into an efficient platform that can be applied quickly to many different cell types and make it possible to produce a lot of different cell therapies in the future. This project will help us understand the complex cell therapy market and to develop our business model and strategy. It will also help us explore some technical challenges that could slow down the adoption of our technology by the wider industry. In conclusion, Plurify will solve a key bottleneck to enable more efficient manufacturing of purer cell therapy products for lower cost so that more and more people can benefit from this next generation of therapies in the near future.

Cell therapies are the next generation of medicines that can potentially cure many diseases including diabetes, heart disease or cancer. While there are some promising approaches already, bringing these treatments to broad application requires improvements in the scale and cost. Pluripotent stem cell derived therapies have the power to do this and can be the key to treat some illnesses that are without a cure so far. However, making the right cell types (e.g. pancreatic cells, heart cells or immune cells) from stem cells can be difficult and lead to some unwanted cells that are either not beneficial for the patient or, in the worst case, can be dangerous. Therefore we need to make sure that cells for therapeutic purposes are clean and safe to use. Plurify is developing a new approach to ensure exactly that. With our technology, we can purify any specific cell type from a mixture of cells that is usually produced when trying to make cells for therapy. This new method can solve one of the key bottlenecks that have been holding back pluripotent stem cells from fulfilling their true potential for cell therapies. With the help of Innovate UK funding, we will be able to develop this technology into an efficient platform that can be applied quickly to many different cell types and make it possible to produce a lot of different cell therapies in the future. What's even better is that our approach is also reducing waste and failures in manufacturing, leading to a more efficient and sustainable process of producing these new cell therapies. This will in turn save costs and make sure that these treatments can reach as many people as possible. In conclusion, Plurify will solve a key bottleneck to enable more efficient manufacturing of purer cell therapy products for lower cost so that more and more people can benefit from this next generation of therapies in the near future.